top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Christopher Gerard net worth and biography

Christopher Gerard Biography and Net Worth

COO of Amedisys

Chris Gerard is President and Chief Operating Officer, overseeing the company’s home health, hospice and personal care divisions.

Gerard has a track record of more than 20 years experience in home health and hospice. He was co-founder, President and Chief Executive Officer of IntegraCare Home Health, where he built a single home health start-up location into 54 branches, generating $71 million in annual revenues. He sold the company to Kindred Healthcare in 2012. He then served as Vice President of South Central Region for the Kindred at Home division, currently a $2.5 billion home health, hospice and community care services business with approximately 700 locations and 42,000 employees nationwide. Gerard was promoted to Chief Operating Officer at Kindred at Home, where he was responsible for integrating a $140 million home health company; standardizing processes across a division involving 187 locations, staff of 3,300 and revenue of $360 million. Most recently, he served as President for the South Central Region of Kindred at Home with responsibility for day-to-day operations, including the integration of the Gentiva Home Health acquisition within his region, oversight of clinical excellence, financial performance and operational efficiencies for 153 home health and hospice locations in six states with annual revenue in excess of $400 million.

Gerard received his Bachelor degree in Finance from Texas Tech University.

What is Christopher Gerard's net worth?: The estimated net worth of Christopher Gerard is at least $3.55 million as of August 2nd, 2021. Mr. Gerard owns 39,006 shares of Amedisys stock worth more than $3,551,496 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Gerard may own. Learn More about Christopher Gerard's net worth.
How do I contact Christopher Gerard?: The corporate mailing address for Mr. Gerard and other Amedisys executives is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. Amedisys can also be reached via phone at (225) 292-2031 and via email at [email protected]. Learn More on Christopher Gerard's contact information.
Has Christopher Gerard been buying or selling shares of Amedisys?: Christopher Gerard has not been actively trading shares of Amedisys within the last three months. Most recently, Christopher Gerard sold 1,250 shares of the business's stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $261.24, for a transaction totalling $326,550.00. Following the completion of the sale, the chief operating officer now directly owns 39,006 shares of the company's stock, valued at $10,189,927.44. Learn More on Christopher Gerard's trading history.
Who are Amedisys' active insiders?: Amedisys' insider roster includes Denise Bohnert (Insider), Sharon Brunecz (Insider), Christopher Gerard (COO), Scott Ginn (CFO), David Kemmerly (Insider), Richard Lechleiter (Director), Michael North (Insider), and Bruce Perkins (Director). Learn More on Amedisys' active insiders.

Christopher Gerard Insider Trading History at Amedisys

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/2/2021	Sell	1,250	$261.24	$326,550.00	39,006
5/25/2021	Sell	1,250	$259.59	$324,487.50	42,756
12/15/2020	Sell	750	$272.56	$204,420.00	28,364
10/15/2020	Sell	1,500	$252.03	$378,045.00	30,570
9/15/2020	Sell	1,500	$239.25	$358,875.00	32,110
8/3/2020	Sell	750	$231.52	$173,640.00	32,906
7/1/2020	Sell	750	$203.43	$152,572.50	33,573
6/1/2020	Sell	750	$189.42	$142,065.00	33,926
5/1/2020	Sell	750	$182.35	$136,762.50	35,150
4/1/2020	Sell	750	$178.13	$133,597.50	35,878
3/9/2020	Sell	750	$165.69	$124,267.50	36,625
1/2/2020	Sell	350	$165.22	$57,827.00	24,091
12/2/2019	Sell	350	$162.97	$57,039.50	24,492
11/1/2019	Sell	350	$145.15	$50,802.50	24,922
10/1/2019	Sell	350	$128.79	$45,076.50	25,239
9/9/2019	Sell	350	$134.79	$47,176.50	25,381
3/11/2019	Sell	2,500	$118.96	$297,400.00	25,731
11/9/2018	Sell	7,892	$119.02	$939,305.84	29,429

Christopher Gerard Buying and Selling Activity at Amedisys

Amedisys Company Overview

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Today's Range

Now: $91.05

$90.80

$91.15

50 Day Range

MA: $92.63

$90.40

$94.50

2 Week Range

Now: $91.05

$73.10

$96.44

Volume

81,355 shs

Average Volume

278,405 shs

Market Capitalization

$2.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86